Hikma Pharmaceuticals Plc (LON:HIK) was downgraded by equities research analysts at Morgan Stanley to an “equal weight” rating in a report issued on Wednesday. They currently have a GBX 1,600 ($21.11) price objective on the stock, down from their previous price objective of GBX 2,050 ($27.04). Morgan Stanley’s price target points to a potential upside of 13.80% from the stock’s current price.
HIK has been the subject of several other reports. Jefferies Group LLC decreased their target price on Hikma Pharmaceuticals Plc from GBX 1,450 ($19.13) to GBX 1,390 ($18.34) and set an “underweight” rating for the company in a research report on Wednesday, June 28th. HSBC Holdings plc decreased their target price on Hikma Pharmaceuticals Plc from GBX 1,700 ($22.42) to GBX 1,410 ($18.60) and set a “reduce” rating for the company in a research report on Tuesday, June 27th. Numis Securities Ltd restated an “add” rating and set a GBX 2,000 ($26.38) target price on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Citigroup Inc. restated a “neutral” rating and set a GBX 1,550 ($20.45) target price on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 28th. Finally, J P Morgan Chase & Co restated a “neutral” rating and set a GBX 1,500 ($19.79) target price on shares of Hikma Pharmaceuticals Plc in a research report on Tuesday, June 27th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,936.10 ($25.54).
Shares of Hikma Pharmaceuticals Plc (LON HIK) opened at 1434.00 on Wednesday. The stock’s market capitalization is GBX 3.46 billion. The firm’s 50-day moving average is GBX 1,471.56 and its 200-day moving average is GBX 1,804.15. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,340.00 and a 1-year high of GBX 2,703.00.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/04/hikma-pharmaceuticals-plc-lonhik-stock-rating-lowered-by-morgan-stanley.html.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.
